News | BRG press release
BRG Wins Healthcare/Life Sciences Deal of the Year at M&A Advisor Turnaround Awards
The M&A Advisor announced BRG as winner of the Healthcare/Life Sciences Deal of the Year (Under $500 million) in its 13th Annual Turnaround Awards. BRG Managing Directors Haywood Miller and Peter Chadwick led a team in the sale of Orexigen Therapeutics, Inc.
“Since 2002, we have been honoring the leading turnaround transactions, companies and dealmakers. BRG was chosen from over 275 participating companies to receive the award. It gives us a great pleasure to recognize BRG and bestow upon it our highest honor for distressed investing and reorganization firms and professionals,” said Roger Aguinaldo, founder of The M&A Advisor. “BRG represents the best of the distressed investing and reorganization industry in 2018 and earned these honors by standing out in a group of very impressive candidates.”
“The Orexigen case was another opportunity for us to take advantage of the wealth of healthcare talent at BRG. BRG’s Healthcare Analytics and Private Equity Finance Advisory teams allowed us to broaden the potential pool of acquirers, ultimately resulting in a robust sale process,” said Chadwick.
BRG’s Corporate Finance group provides multidisciplinary services, including transaction opinions, transaction advisory services and restructuring, to companies, fiduciaries, lenders, attorneys, funds and other investors. BRG professionals’ leading-edge insights as advisors, crisis managers and corporate officers in middle-market to multinational restructurings across a diverse number of industries let them quickly present practical alternatives, design strategies that help maximize value and recommend the most viable approaches. The Corporate Finance team’s broad scope of restructuring and bankruptcy services spans areas that include financial analysis, plan development and implementation, and advice on sale/merger transactions.
BRG provides pre-transaction, transaction and post-transaction valuation advisory services, including diligence, fairness and solvency opinions, alternative investment portfolio valuations and post-transaction disputes.